IP Library Granted Patent US 7,332,288
Granted Patent B2
US 7,332,288 · App. 10/269,579 · Granted Feb 19, 2008

Methods and reagents for the rapid and efficient isolation of circulating cancer cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,288
App. No.
10/269,579
Granted
Feb 19, 2008
Kind
B2
Abstract

A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric and immunocytochemical analysis to detect, enumerate and characterize carcinoma cells in the blood. The assay can detect one epithelial cell or less in 1 ml of blood and has a greater sensitivity than conventional PCR or immunohistochemistry by 1-2 orders of magnitude. In addition, the assay facilitates the biological characterization and staging of carcinoma cells.

Claims (9)

1. A coated magnetic particle comprising a nanoparticle core material of magnetite, a protein base coating material of bovine serum albumin directly coated onto quasi-stable crystalline clusters of said core material and an additional streptavidin coating coupled to said base coating material, wherein a fraction of the streptavidin which is coupled to said base coating material is bound to biotinylated antibody and substantial portion of said streptavidin remaining is bound to biotin-bovine serum albumin conjugate.

2. A composition comprising a plurality of magnetic particles as claimed in claim 1 , suspended in a biologically compatible aqueous medium.

3. A coated, magnetic particle within a population of coated, magnetic nanoparticles, said coated, magnetic particle comprising:

a. a fractionated nanoparticle core between 90 nm and 150 nm that provides between 83% and 93% target recovery in external magnetic gradient wherein said core comprises at least one transition metal oxide;

b. a base coating material adsorbed onto said nanoparticle core wherein said material comprises a protein directly coated onto a quasi-stable crystalline cluster of said fractionated nanoparticle core; and

c. an additional streptavidin coating coupled to said base coating material, wherein a fraction of the streptavidin which is coupled to said base coating material is bound to biotinylated antibody and substantial portion of said streptavidin remaining is bound to biotin-bovine serum albumin conjugate.

4. A coated magnetic particle comprising a nanoparticle core material having a magnetic transition metal oxide core, a protein base coating material coated on the nanoparticle core and an additional streptavidin coating coupled to said base coating material through a bifunctional linking compound, wherein a fraction of the streptavidin which is coupled to said base coating material is bound to biotinylated antibody and substantial portion of said streptavidin remaining is bound to biotin-bovine serum albumin conjugate.

5. The coated magnetic particle of claim 4 wherein said bifunctional compound is succinimidyl-propiono-dithiopyridine or sulfosuccinimidil-4-[maleimidomethyl]cyclohexane-1-carboxylate.

6. The coated magnetic particle of claim 4 wherein said magnetic transition metal oxide core is magnetite.

Assignments (4)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 4, 2019
From: MENARINI SILICON BIOSYSTEMS, INC.
To: MENARINI SILICON BIOSYSTEMS S.P.A.
Reel/Frame 049631/0823 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: JANSSEN DIAGNOSTICS, LLC
To: MENARINI SILICON BIOSYSTEMS, INC.
Reel/Frame 045238/0050 →
CHANGE OF NAME Recorded Dec 6, 2013
From: VERIDEX, LLC
To: JANSSEN DIAGNOSTICS, LLC
Reel/Frame 031970/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2008
From: IMMUNICON CORP.
To: VERIDEX, LLC
Reel/Frame 021334/0454 →